-- Poster presentation of MGTA-145 investigator-initiated Phase 2 clinical trial data confirmed previously reported positive topline clinical data for stem cell mobilization and transplant in multiple ...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more ...

- Ongoing clinical trial is the first ever to combine targeted radiotherapy conditioning, Iomab-ACT, with CAR-T cell therapy to achieve lymphodepletion along with reduction of cytokine release ...

Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a multi-billion market with six FDA approved therapies totaling sales over $3.5 billion ...

Technology has moved the world forward in so many ways. Yet, among those who focus on the way technology has affected psychological aspects, there have long been concerns expressed. From Jon ...

Please provide your email address to receive an email when new articles are posted on . Three patients with sickle cell disease who received the investigational gene therapy ARU-1801 achieved and ...